Third Rock startup MyoKardia staggered onto Nasdaq on Wednesday, pricing its IPO at $10 a share--a deep, bargain basement discount from the hefty range it set for itself.
MyoKardia, expected to go public this week, is poised to become the next barometer of biotech's status on Wall Street, angling for a $75 million debut as investors take a tepid approach to drug developers.
MyoKardia, taking a rare disease approach to cardiovascular drug development, is plotting to go public in an $86 million IPO and raise cash to push its Sanofi-partnered pipeline.
Sanofi partner MyoKardia is getting a fresh injection of capital, garnering $46 million in its Series B as the South San Francisco-based biotech plots the next stage of its clinical journey developing new drugs for genetically defined groups of heart patients.
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...
Third Rock Ventures has dipped back into its second fund for a $38 million A round to launch a new drug developer which plans to get into the genetic nitty-gritty of heart disease.